EPISODE · Jun 30, 2022 · 31 MIN
Advocacy Roundtable Discussion
from ASHPOfficial · host American Society of Health-System Pharmacists©
Listen to our Advocacy Roundtable Discussion with ASHP’s government relations team regarding our top advocacy priorities. This discussion with Tom Kraus, vice president of government relations, Jillanne Schulte Wall, senior director of Health and Regulatory Policy, and Kyle Robb, director of state policy advocacy, provides ASHP members with an inside look at federal advocacy topics impacting the practice of pharmacy. Topics discussed include pharmacist provider status, 340B, elimination of the X-waiver for buprenorphine prescribing, white bagging, and more. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
What this episode covers
Listen to our Advocacy Roundtable Discussion with ASHP’s government relations team regarding our top advocacy priorities. This discussion with Tom Kraus, vice president of government relations, Jillanne Schulte Wall, senior director of Health and Regulatory Policy, and Kyle Robb, director of state policy advocacy, provides ASHP members with an inside look at federal advocacy topics impacting the practice of pharmacy. Topics discussed include pharmacist provider status, 340B, elimination of the X-waiver for buprenorphine prescribing, white bagging, and more. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
NOW PLAYING
Advocacy Roundtable Discussion
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.